Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28446565 | 0.85 | — | — | |
| SCHEMBL27775728 | 0.74 | KDM4E (0.33) | KDM4ETDP1 | |
| SCHEMBL27493381 | 0.73 | — | — | |
| SCHEMBL28437375 | 0.73 | — | — | |
| SCHEMBL17733552 | 0.72 | KDM4E (0.32) | KDM4ETDP1 | |
| SCHEMBL27578961 | 0.71 | — | — | |
| SCHEMBL3585321 | 0.70 | KDM4E (0.33) | KDM4ETDP1ALDH1A1MAPTLMNA | |
| SCHEMBL13342856 | 0.69 | KDM4E (0.31) | KDM4ETDP1 | |
| SCHEMBL29246420 | 0.69 | HRH3 (0.31) | — | |
| SCHEMBL15088774 | 0.69 | KDM4E (0.34) | KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697789-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2020-08-26 | — | — | EP | claimed |
| CN-111542526-A | Condensed imidazole derivatives substituted by tertiary hydroxyl group as PI 3K-gamma inhibitor | 因赛特公司 | 2020-08-14 | — | — | CN | claimed |
| WO-2019079469-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2019-04-25 | — | — | WO | claimed |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| CN-118063470-A | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11926630-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| EP-4006034-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11225486-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3697789-B1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20200385392-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| EP-3697789-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2020-08-26 | — | — | EP | disclosed |
| CN-111542526-A | Condensed imidazole derivatives substituted by tertiary hydroxyl group as PI 3K-gamma inhibitor | 因赛特公司 | 2020-08-14 | — | — | CN | disclosed |
| US-10738057-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-05-23 | — | — | US | disclosed |
| WO-2019079469-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2019-04-25 | — | — | WO | disclosed |
| CN-106458983-A | Novel compound | 拜耳制药股份公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | KDM4E 3139/4885TDP1 609/4885ADRA2C 3344/4885 |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | KDM4E 3139/4885TDP1 609/4885ADRA2C 3344/4885 |
| US-10738057-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | KDM4E 4006/4885TDP1 619/4885ADRA2C 2949/4885 |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | KDM4E 3139/4885TDP1 609/4885ADRA2C 3344/4885 |
| US-20200385392-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | KDM4E 3139/4885TDP1 609/4885ADRA2C 3344/4885 |
| US-11225486-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | KDM4E 4006/4885TDP1 619/4885ADRA2C 2949/4885 |
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | KDM4E 557/4885TDP1 451/4885ADRA2C 3317/4885 |
| US-11926630-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | KDM4E 4006/4885TDP1 619/4885ADRA2C 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.